Results for the intent-to-treat population; includes 619 patients (25.2%) who crossed over to letrozole from tamoxifen. § Results for the censored population (with 95% CI); excludes crossover ...

Aromatase inhibitors (AIs) are becoming the hormonal ... or anastrozole versus the previous standard of 5 years of adjuvant tamoxifen and support using an AI (exemestane, anastrozole or letrozole ...

Around 80% of breast cancers are ER+ and are treated with anti-oestrogen therapies such as tamoxifen and aromatase inhibitors. But around one in five of these cases recur within 10 years, and nearly ...

There are three aromatase inhibitors available: Faslodex belongs to a group of medicines known as hormonal or endocrine therapy. It works as an estrogen receptor blocker. Faslodex is given as an ...